• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

KTE-X19 may induce remission in patients with relapsed or refractory B-cell lymphoblastic leukemia

byNeel MistryandTeddy Guo
August 17, 2021
in Chronic Disease, Hematology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. 71% patients achieved complete remission or complete remission with incomplete recovery following KTE-X19 infusion.

2. The majority of adverse events were mild, with two grade 5 KTE-X19-related events. 

Evidence Rating Level: 2 (Good)

Study Rundown: Refractory B-cell precursor acute lymphoblastic leukemia remains common despite advancements in treatment. Agents such as blinatumomab and inotuzumab, combined with allogeneic stem-cell transplant, are often used to achieve clinical remission in such patients. However, the 1-year survival rate and risk of remission continue to be concerning statistics. For these reasons, an alternative therapy must be looked into. This phase II open-label study aimed to report the safety and efficacy of KTE-X19 – a chimeric antigen receptor (CAR) T-cell therapy targeting the CD19 receptor – in adult patients with B-cell lymphoblastic leukemia. The primary outcome was the rate of complete remission or remission with incomplete recovery, while key secondary outcomes included minimal residual disease (MRD) negativity rate, duration of remission, and overall survival. According to study results, administration of KTE-X19 resulted in complete remission or remission with incomplete recovery in nearly three-quarters of patients in this study. Furthermore, MRD negativity was reported among the majority of patients, although the sample size was too low to ensure validity. This study suggests that KTE-X19 may serve as an important therapeutic option in patients with refractory B-cell lymphoblastic leukemia.

Click to read the study in The Lancet

Relevant Reading: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

In-depth [randomized controlled trial]: Between Oct 1, 2018, and Oct 9, 2019, 71 patients were enrolled and underwent leukapheresis from 25 centers in the USA, Canada, and Europe. Included patients were ≥18 years with an Eastern Cooperative Oncology Group (ECOG) rating of 0-1 and recurrent leukemia, defined as >5% lymphoblasts in the bone marrow. 16 patients were excluded due to the occurrence of adverse events and lack of eligibility from the study. Altogether, 55 patients received KTE-X19 and were included in the modified intention-to-treat analysis.

RELATED REPORTS

#VisualAbstract: Rituximab plus lenalidomide shows comparable survival compared to chemotherapy for CD20⁺ follicular lymphoma

#VisualAbstract: Odronextamab shows promising clinical activity in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

The median age among treated patients was 40 years (interquartile range [IQR] 28-52) while median follow-up time was 16.4 months (IQR 13.8-19.6). The primary outcome of overall clinical remission or remission with incomplete hematologic recovery was observed in 39 patients (71%, 95% confidence interval [CI] 57-82, p<0.0001) with 31 (56%) patients achieving complete remission. With regard to key secondary outcomes, patients remained in complete remission for a median duration of 12.8 months after receiving KTE-X19 and reported a median overall survival of 18.2 months since the administration of therapy. Moreover, MRD negativity was close to 100% (38 of 39, 97%) in patients who experienced clinical remission. The most common grade 3 or greater adverse events following infusion were anemia (49%), pyrexia (36%), and hypotension (29%). Although most events were mild in nature, two grade 5 events (brain herniation and septic shock) were reported. Overall, KTE-X19 showed promise in achieving complete remission and could be considered as a potential therapeutic option in patients with refractory B-cell acute lymphoblastic leukemia.

Image: PD 

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: acute lymphoblastic leukemiaacute lymphoblastic leukemia (ALL)B-cell acute lymphoblastic leukemiaB-cell malignancyCAR T cellschimeric antigen receptor (CAR) T-cell therapyhematologic cancerhematologic malignancyKTE-X19relapsed refractory b-precursor acute lymphoblastic leukemia
Previous Post

Differences in national strategies for the treatment of relapsing-remitting multiple sclerosis significantly associated with disability outcomes during follow-up

Next Post

Breastfeeding not associated with late-onset group B Streptococcus disease in infants

RelatedReports

#VisualAbstract: Chemoradiotherapy with carboplatin is more effective than cetuximab in head and neck squamous cell carcinoma
StudyGraphics

#VisualAbstract: Rituximab plus lenalidomide shows comparable survival compared to chemotherapy for CD20⁺ follicular lymphoma

October 19, 2022
#VisualAbstract: Odronextamab shows promising clinical activity in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
StudyGraphics

#VisualAbstract: Odronextamab shows promising clinical activity in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

April 23, 2022
#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia
StudyGraphics

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

April 8, 2022
#VisualAbstract: Immunocompromised individuals may be at an increased risk of metastses with cutaneous squamous cell carcinomas
StudyGraphics

#VisualAbstract: Immunocompromised individuals may be at an increased risk of metastses with cutaneous squamous cell carcinomas

March 22, 2022
Next Post
Higher blood pressure targets in sepsis did not reduce mortality

Breastfeeding not associated with late-onset group B Streptococcus disease in infants

Influenza vaccine not associated with increased risk of epilepsy in children

COVID-19 vaccinations during pregnancy: coverage and safety

Quick Take: Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG)

Impact of antibiotic pretreatment on cultures in children with osteomyelitis and septic arthritis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Chronic obstructive pulmonary disease associated with worse postoperative outcomes
  • Empagliflozin use is associated with slower progression of chronic kidney disease
  • Diagnostic tool may help identify cerebral palsy regardless of encephalopathy features
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options